MoonLake ImmunotherapeuticsMEX:MLTXN 30 Piotroski F-Score is 1 as of Jun. 26, 2026, which is at its 10-year median of 1.00. GuruFocus rates MEX:MLTXN with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,342 Biotechnology companies, MoonLake Immunotherapeutics ranks worse than 92.32% on this metric.
Warning Sign:
Piotroski F-Score of 1 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
MoonLake Immunotherapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
The historical rank and industry rank for MoonLake Immunotherapeutics's Piotroski F-Score or its related term are showing as below:
MEX:MLTXN'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 1 Max: 3
Current: 1
During the past 5 years, the highest Piotroski F-Score of MoonLake Immunotherapeutics was 3. The lowest was 1. And the median was 1.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
MoonLake Immunotherapeutics Piotroski F-Score Related Terms
MoonLake Immunotherapeutics Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:MLTXN vs AVBP, BCAX, KALV: Piotroski F-Score Comparison
For the Biotechnology subindustry, MoonLake Immunotherapeutics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MoonLake Immunotherapeutics Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MoonLake Immunotherapeutics's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where MoonLake Immunotherapeutics's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Mar26) TTM:
Last Year (Mar25) TTM:
Net Income was -1039.748 + -1279.123 + -1124.042 + -1257.005 = MXN-4,699.92 Mil. Cash Flow from Operations was -1026.756 + -817.106 + -1058.627 + -1195.316 = MXN-4,097.81 Mil. Revenue was 0 + 0 + 0 + 0 = MXN0.00 Mil. Gross Profit was 0 + 0 + 0 + 0 = MXN0.00 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(10459.5 + 8663.24 + 7600.644 + 7642.213 + 7219.824) / 5 = MXN8317.0842 Mil. Total Assets at the begining of this year (Mar25) was MXN10,459.50 Mil. Long-Term Debt & Capital Lease Obligation was MXN1,801.16 Mil. Total Current Assets was MXN7,152.51 Mil. Total Current Liabilities was MXN831.56 Mil.
Net Income was -444.574 + -696.84 + -951.124 + -817.182 = MXN-2,909.72 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
MoonLake Immunotherapeutics's current Net Income (TTM) was -4,699.92.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
MoonLake Immunotherapeutics's current Cash Flow from Operations (TTM) was -4,097.81.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
MoonLake Immunotherapeutics's return on assets of this year was -0.44934442. MoonLake Immunotherapeutics's return on assets of last year was -0.31079348.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
MoonLake Immunotherapeutics's gearing of this year was 0.21656147. MoonLake Immunotherapeutics's gearing of last year was 0.15180105.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
MoonLake Immunotherapeutics's current ratio of this year was 8.60131319. MoonLake Immunotherapeutics's current ratio of last year was 21.11104996.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
MoonLake Immunotherapeutics's number of shares in issue this year was 71.274. MoonLake Immunotherapeutics's number of shares in issue last year was 63.234.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
MoonLake Immunotherapeutics's gross margin of this year was . MoonLake Immunotherapeutics's gross margin of last year was .
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
MoonLake Immunotherapeutics's asset turnover of this year was 0. MoonLake Immunotherapeutics's asset turnover of last year was 0.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
0
+
1
+
0
+
0
+
0
+
0
+
0
=
1
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
MoonLake Immunotherapeutics has an F-score of 1. It is a bad or low score, which usually implies poor business operation.
MoonLake Immunotherapeutics (MEX:MLTXN) has a Piotroski F-Score of 1 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on MoonLake Immunotherapeutics and its competitors. This is near median its historical median of 1.00. Over the past decade, MoonLake Immunotherapeutics' Piotroski F-Score has ranged from 1.00 to 3.00. According to the industry distribution chart, MoonLake Immunotherapeutics ranks #1239 out of 1342 companies in the Biotechnology industry, placing it in the top 92.3%.
Is MoonLake Immunotherapeutics' Piotroski F-Score too high?
MoonLake Immunotherapeutics' current Piotroski F-Score of 1 is near median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 3.00. The Biotechnology industry median Piotroski F-Score is 3.00. MoonLake Immunotherapeutics' value of 1 is 66.7% below this industry median. Based on the distribution chart, MoonLake Immunotherapeutics ranks #1239 out of 1342 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MoonLake Immunotherapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does MoonLake Immunotherapeutics' Piotroski F-Score compare to AVBP and BCAX?
According to the Biotechnology industry distribution chart, MoonLake Immunotherapeutics ranks #1239 out of 1342 companies for Piotroski F-Score. This places MoonLake Immunotherapeutics in the lower half of its industry. The industry median Piotroski F-Score is 3.00. MoonLake Immunotherapeutics' value of 1 is 66.7% below this benchmark. Historically, MoonLake Immunotherapeutics' own Piotroski F-Score has ranged from 1.00 to 3.00 over the past decade. While the company's 10-year median is 1.00 vs. the industry median of 3.00, MoonLake Immunotherapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MoonLake Immunotherapeutics's current Piotroski F-Score of 1 is 66.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on MoonLake Immunotherapeutics and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MoonLake Immunotherapeutics's current Piotroski F-Score is 1, which is near median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MoonLake Immunotherapeutics stock overvalued right now?
MoonLake Immunotherapeutics (MEX:MLTXN) has a current Piotroski F-Score of 1. The current Piotroski F-Score is 1, which is near median its 10-year median of 1.00 and 66.7% below the Biotechnology industry median of 3.00. MoonLake Immunotherapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For MoonLake Immunotherapeutics (MEX:MLTXN), the current Piotroski F-Score is 1 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
30GF Score
Get the complete analysis for MEX:MLTXN
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MLTXN has been successfully added to your 
